Exo Therapeutics Launches $ 25 Million Series A Funding to Unlock Insoluble Drug Targets with Exosites
CAMBRIDGE, Mass .– (COMMERCIAL THREAD) –Exo-Therapeutic, Inc., a small molecule drug discovery and development company with pioneering technology to address insoluble pharmaceutical targets, today announced completion of a $ 25 million Series A funding. Investors in the round included Newpath Partners, Novartis Venture Fund, CRV and 6 Dimensions Capital.
Exo is building an extensive pipeline of drug candidates that bind exosites, unique, distal binding pockets that reprogram enzyme activity for a precise and robust therapeutic effect. Based on research from the laboratories of Professors David Liu and Alan Saghatelian, the company’s exclusive ExoSightMT The platform is based on advancements in several technologies that enable the discovery and optimization of exosite drugs, including structural and computational biology, protein engineering, and DNA-encoded libraries. Focusing on exosites overcomes the common challenges of competitive binding and off-target activity that occur with active site and allosteric modulators, potentially producing better therapeutic windows, greater selectivity, and fewer side effects.
“Exo is at the forefront of integrated exosite science, aimed at unlocking previously insoluble drug targets, ”said Michael Bruce, PhD, CEO of Exo Therapeutics. “We seek to leverage the unparalleled expertise of our team and focus on treating exosites as we move towards proof of concept drugs as we move forward into the clinic. With the support of world-class investors and rigorous fundamental science, we are well equipped to advance our portfolio of oncology and inflammation drug candidates in 2021. ”
“Exosites are compelling therapeutic targets because they avoid the common challenges of targeting enzymes and are ubiquitous in the proteome, allowing for broad therapeutic potential, ”said Alan Saghatelian, PhD, Dr Frederik Paulsen Chair, Salk Institute for Biological Studies .
“Exosites have demonstrated their ability to modulate cellular targets with precision and power. The challenges of selectivity and traditional active site targeting are areas I have focused on since my graduate studies in receptors, ”said Thomas Cahill, MD, PhD, Founder and Managing Partner of Newpath Partners. “The foundational work of Professors Liu and Saghatelian provides elegant solutions for Exo to overcome these challenges. Additionally, an experienced SAB with experience in developing potent therapies uniquely positions the company to develop a new class of small molecule drugs. ”
Proceeds from the funding will be used to advance therapeutic candidates derived from the Company’s ExoSightMT platform towards proof of concept and in the clinic. Exo is developing an initial portfolio of programs focused on oncology and inflammation by modulating enzyme activity in pathways where exosites are prevalent. The team expects to find exosites in many important pathogen pathways and will engage in strategic partnerships with biopharmaceutical companies.
In addition to Professors Liu and Saghatelian, Exo has assembled a Scientific Advisory Board that includes Professor Stuart Schreiber of the Broad Institute at MIT and Harvard, Professor Ben Cravatt, PhD of the Scripps Research Institute, and Professor Ben Ebert, MD, PhD of the Dana Farber Cancer Institute. Exo is experienced, collaborative and dedicated team is passionate about the pioneering science of exosites to unlock revolutionary therapies.
About Exo Therapeutics
Exo Therapeutics is a small molecule drug discovery and development company with pioneering technology to treat insoluble pharmaceutical targets. By leveraging the company’s ExoSightMT platform, Exo is developing a broad portfolio of potent drug candidates that bind to exosites, distal and unique binding pockets that have the potential to reprogram enzyme activity for precise and robust therapeutic effect. Through this specific and selective approach to difficult targets, the company’s team of world-class researchers are pioneering breakthrough therapeutic avenues in oncology, inflammation and a wide range of other diseases. For more information visit www.exo-therapeutics.com.